Company intelligence / Profile preview

SBT Science and Biotechnologies

Madrid, Madrid, Spain

Ownership: Private
Development stage: Other

Overview

SBT Science and Biotechnologies is a biotechnology company based in Spain that specializes in the field of regenerative medicine and autologous biological therapies. The company focuses on the development and commercialization of advanced systems for Platelet-Rich Plasma (PRP) and growth factor concentration, marketed under the brand SBT Human. Their technology is primarily utilized in orthopedics, sports medicine, and aesthetic dermatology to accelerate tissue repair and promote cellular regeneration. SBT provides medical professionals with specialized kits and processing equipment designed to optimize the therapeutic potential of a patient's own biological components.

Therapeutic areas: OtherRheumatologyDermatology
Modalities: Cell therapyProteinPlatelet-rich plasma
Industry: Biotech

Beyond the preview

Go deeper on SBT Science and Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT Science and Biotechnologies.

Explore the full profile